Exercise-induced Erythropoiesis: the Mechnistic of Angiotensin II

• Status: Not yet recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The major aims are to determine the effect of acute (single dose) blockade of ANGII receptor 1 (AT1) on the EPO response to a single session of endurance exercise, as well as determine the effect of chronic (8-week) blockade of AT1 on ET-induced adaptations in total circulating red blood volume and hemoglobin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Valsartan

Criteria

Inclusion Criteria:

• Healthy status, absence of current medical symptoms or medication limiting incremental exercise testing

• No history of cardiac, pulmonary or kidney disease.

Exclusion Criteria:

• Individuals fulfilling the above criteria but currently involved in regular exercise training (> 5 hr/week)